Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 96 Präparate · 6744 Quellenpassagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Tasmar
Tasmar 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-086558 · Präparat HOS-083306
Tasmar, as a COMT inhibitor, is known to increase the bioavailability of the co-administered levodopa.
The consequent increase in dopaminergic stimulation can lead to the dopaminergic adverse reactions
observed after treatment with COMT inhibitors. The most common of these are increased dyskinesia,
nausea, vomiting, abdominal pain, syncope, orthostatic complains, constipation, sleep disorders,
somnolence, hallucination.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): levodopa (HOS-086559) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage 523a820e1ad29c7fad66d24b65a0c98c367c000c95c5543f0b30468d739b5df3 · Zeichen 0–423 im Abschnitt
Wechselwirkungen · Tasmar
Tasmar 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-086560 · Präparat HOS-083306
Levodopa has been associated with somnolence and episodes of sudden sleep onset. Sudden onset of
sleep during daily activities, in some cases without awareness or warning signs, has been reported very
rarely. Patients must be informed of this and advised to exercise caution while driving or operating
machines during treatment with levodopa. Patients who have experienced somnolence and/or an episode
of sudden sleep onset must refrain from driving or operating machines (see section 4.7). Furthermore a
reduction of levodopa dose or termination of therapy may be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): levodopa (HOS-086559)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage 75147e88f8b0298ea0eb0ffdc24266ffc8832af4ccfe165521eded80494f25ec · Zeichen 425–1001 im Abschnitt
Wechselwirkungen · Tasmar
Tasmar 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6
HOS-086561 · Präparat HOS-083306
Catechols and other drugs metabolised by catechol-O-methyltransferase (COMT)
Tolcapone may influence the pharmacokinetics of drugs metabolised by COMT. No effects were seen
on the pharmacokinetics of the COMT substrate carbidopa. An interaction was observed with
benserazide, which may lead to increased levels of benserazide and its active metabolite. The magnitude
of the effect was dependent on the dose of benserazide. The plasma concentrations of benserazide
observed after co-administration of tolcapone and benserazide-25 mg/levodopa were still within the
range of values observed with levodopa/benserazide alone. On the other hand, after coadministration of
tolcapone and benserazide-50 mg/levodopa the benserazide plasma concentrations could be increased
above the levels usually observed with levodopa/benserazide alone. The effect of tolcapone on the
pharmacokinetics of other drugs metabolised by COMT such as -methyldopa, dobutamine,
apomorphine, adrenaline and isoprenaline have not been evaluated. The prescriber should be observant
of adverse reactions caused by putative increased plasma levels of these drugs when combined with
Tasmar.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): levodopa (HOS-086559) methyldopa (HOS-086564) dobutamine (HOS-086565) apomorphine (HOS-086566) carbidopa (HOS-086562) benserazide (HOS-086563) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage e79962e4782917307a0da569a9c64d5fe16790a76c30db979f6d915f33b0c1f7 · Zeichen 1003–2156 im Abschnitt
Wechselwirkungen · Tasmar
Tasmar 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 6–7
HOS-086571 · Präparat HOS-083306
6
When Tasmar was given together with levodopa/carbidopa and desipramine, there was no significant
change in blood pressure, pulse rate and plasma concentrations of desipramine. Overall, the frequency
of adverse reactions increased slightly. These adverse reactions were predictable based on the known
adverse reactions to each of the three drugs individually. Therefore, caution should be exercised when
potent noradrenaline uptake inhibitors such as desipramine, maprotiline, or venlafaxine are administered
to Parkinson’s disease patients being treated with Tasmar and levodopa preparations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): desipramine (HOS-086249) maprotiline (HOS-086572) venlafaxine (HOS-086573) levodopa (HOS-086559) carbidopa (HOS-086562)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage f0044f3a960b0b3d966c24892293ccebf08b5ee7404000f75c3cf3acef4c3a06 · Zeichen 2983–3578 im Abschnitt
Wechselwirkungen · Tasmar
Tasmar 100 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-086574 · Präparat HOS-083306
In clinical trials, patients receiving Tasmar/levodopa preparations reported a similar adverse reaction
profile independent of whether or not they were also concomitantly administered selegiline (a MAO-B
inhibitor).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): levodopa (HOS-086559) selegiline (HOS-086575)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage 2f2c2346d0db6914c588a4768021e36549ed91e363df03edd5390e458ac88fce · Zeichen 3580–3795 im Abschnitt
Wechselwirkungen · Tasmar
Tasmar 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18
HOS-086590 · Präparat HOS-083306
Tasmar, as a COMT inhibitor, is known to increase the bioavailability of the co-administered levodopa.
The consequent increase in dopaminergic stimulation can lead to the dopaminergic adverse reactions
observed after treatment with COMT inhibitors. The most common of these are increased dyskinesia,
nausea, vomiting, abdominal pain, syncope, orthostatic complains, constipation, sleep disorders,
somnolence, hallucination.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): levodopa (HOS-086559) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage 523a820e1ad29c7fad66d24b65a0c98c367c000c95c5543f0b30468d739b5df3 · Zeichen 0–423 im Abschnitt
Wechselwirkungen · Tasmar
Tasmar 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18
HOS-086591 · Präparat HOS-083306
Levodopa has been associated with somnolence and episodes of sudden sleep onset. Sudden onset of
sleep during daily activities, in some cases without awareness or warning signs, has been reported very
rarely. Patients must be informed of this and advised to exercise caution while driving or operating
machines during treatment with levodopa. Patients who have experienced somnolence and/or an episode
of sudden sleep onset must refrain from driving or operating machines (see section 4.7). Furthermore a
reduction of levodopa dose or termination of therapy may be considered.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): levodopa (HOS-086559)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage 75147e88f8b0298ea0eb0ffdc24266ffc8832af4ccfe165521eded80494f25ec · Zeichen 425–1001 im Abschnitt
Wechselwirkungen · Tasmar
Tasmar 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18
HOS-086592 · Präparat HOS-083306
Catechols and other drugs metabolised by catechol-O-methyltransferase (COMT)
Tolcapone may influence the pharmacokinetics of drugs metabolised by COMT. No effects were seen
on the pharmacokinetics of the COMT substrate carbidopa. An interaction was observed with
benserazide, which may lead to increased levels of benserazide and its active metabolite. The magnitude
of the effect was dependent on the dose of benserazide. The plasma concentrations of benserazide
observed after co-administration of tolcapone and benserazide-25 mg/levodopa were still within the
range of values observed with levodopa/benserazide alone. On the other hand, after coadministration of
tolcapone and benserazide-50 mg/levodopa the benserazide plasma concentrations could be increased
above the levels usually observed with levodopa/benserazide alone. The effect of tolcapone on the
pharmacokinetics of other drugs metabolised by COMT such as -methyldopa, dobutamine,
apomorphine, adrenaline and isoprenaline have not been evaluated. The prescriber should be observant
of adverse reactions caused by putative increased plasma levels of these drugs when combined with
Tasmar.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): levodopa (HOS-086559) methyldopa (HOS-086564) dobutamine (HOS-086565) apomorphine (HOS-086566) carbidopa (HOS-086562) benserazide (HOS-086563) lead (HOS-085592)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage e79962e4782917307a0da569a9c64d5fe16790a76c30db979f6d915f33b0c1f7 · Zeichen 1003–2156 im Abschnitt
Wechselwirkungen · Tasmar
Tasmar 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 18–19
HOS-086596 · Präparat HOS-083306
18
When Tasmar was given together with levodopa/carbidopa and desipramine, there was no significant
change in blood pressure, pulse rate and plasma concentrations of desipramine. Overall, the frequency
of adverse reactions increased slightly. These adverse reactions were predictable based on the known
adverse reactions to each of the three drugs individually. Therefore, caution should be exercised when
potent noradrenaline uptake inhibitors such as desipramine, maprotiline, or venlafaxine are administered
to Parkinson’s disease patients being treated with Tasmar and levodopa preparations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): desipramine (HOS-086249) maprotiline (HOS-086572) venlafaxine (HOS-086573) levodopa (HOS-086559) carbidopa (HOS-086562)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage b4c09358b64cd61c631b98ee7ba8a6fd06fdf4cab95eeb6c6db1a7ea0d8dd1d1 · Zeichen 2981–3577 im Abschnitt
Wechselwirkungen · Tasmar
Tasmar 200 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 19
HOS-086597 · Präparat HOS-083306
In clinical trials, patients receiving Tasmar/levodopa preparations reported a similar adverse reaction
profile independent of whether or not they were also concomitantly administered selegiline (a MAO-B
inhibitor).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): levodopa (HOS-086559) selegiline (HOS-086575)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-10T13:49:00Z · SHA-256 8ce859140f9a095e62d5fef3a3e25bd89320c57ae3e287a376abb5c14d6c4437 · Passage 2f2c2346d0db6914c588a4768021e36549ed91e363df03edd5390e458ac88fce · Zeichen 3579–3794 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.